The burden and management of patients with IBS: results from a survey in Spanish gastroenterologists

Similar documents
Accepted Article. Irritable bowel syndrome (IBS) subtypes: Nothing. Fermín Mearin Manrique. DOI: /reed /2016 Link: PDF

Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

Alternating bowel pattern: what do people mean?

A Prospective Assessment of Bowel Habit in Irritable Bowel Syndrome in Women: Defining an Alternator

Prevalence and management of abdominal cramping and pain: a multinational survey

Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population

Gastrointestinal Society 2016 SURVEY RESULTS

Epidemiology and Impact of IBS

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 June 2011

REVIEW ARTICLE. Evidence- and Consensus-Based Practice Guidelines for the Diagnosis of Irritable Bowel Syndrome

J Neurogastroenterol Motil, Vol. 16 No. 2 April, 2010 DOI: /jnm Journal of Neurogastroenterology and Motility

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey

JNM Journal of Neurogastroenterology and Motility

Title: Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Applying Case Definition Criteria to Irritable Bowel Syndrome

Comparison of strategies and goals for treatment of chronic constipation among gastroenterologists and general practitioners

Why does my stomach hurt? Exploring irritable bowel syndrome

Vicente Garrigues, Consuelo Gálvez, Vicente Ortiz, Marta Ponce, Pilar Nos, and Julio Ponce

Title: Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome

White Rose Research Online URL for this paper: Version: Accepted Version

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

WOMEN WITH IRRITABLE BOWEL SYNDROME ACCORDING TO ROME II CRITERIA IN JORDAN

Irritable bowel syndrome (IBS) is a

References. AMITIZA [package insert]. Bethesda, MD: Takeda Pharmaceuticals America., Inc; Takeda Pharmaceuticals America, Inc. Data on File.

Review article: irritable bowel syndrome an evidence-based approach to diagnosis

IBS current status Peter Laszlo Lakatos

White Rose Research Online URL for this paper:

Irritable bowel syndrome (IBS) is a ... PRESENTATION... Defining and Diagnosing Irritable Bowel Syndrome

Irritable bowel syndrome: An overview of diagnosis and pharmacologic treatment

AN EXPERT SYSTEM FOR THE DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

Diagnosis and Treatment of Irritable Bowel Syndrome

Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care A Rome Foundation Working Team Report

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Author's personal copy

Copyright note. Wensaas 1


TREATMENT SOCIETY GUIDELINES FOR CONSTIPATION: WHAT IS NEW? FUNCTIONAL CONSTIPATION

Follow this and additional works at:

Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Bloating, Flatulence, and

Diverse pathophysiologic mechanisms, alone or in combination,

Management of Functional Bowel Disorders

Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment

UKLIN1693a, date of preparation: March 2013.

Mirtazapine in diarrhea-predominant irritable bowel syndrome: an openlabel

Diagnostic value of the Manning criteria in irritable bowel syndrome

What should be the primary end point in irritable bowel syndrome?

International Journal of Scientific & Engineering Research, Volume 8, Issue 12, December-2017 ISSN

The diagnosis of IBS in primary care: consensus development using nominal group technique

Irritable bowel syndrome among nurses and nursing students in Brunei Darussalam

Delfini Group, LLC Evidence & Value based Solutions For Health Care Clinical Improvement Consults, Content, Seminars, Training & Tools

IBS and Functional GI Disorders (FGIDs)

The 2012 SAGE Wait Time Program: Survey of Access to GastroEnterology in Canada Can J Gastroenterol 2013;27:83-9.

Psycho-pharmacologic Therapy. Objectives

The impact of Irritable Bowel Syndrome on health-related quality of life: a Singapore perspective

ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response

Systematic review: the effects of fibre in the management of chronic idiopathic constipation

IBS: overview and assessment of pain outcomes and implications for inclusion criteria

This is a repository copy of Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?.

IBS IBS. irritable bowel syndrome IBS IBS. in situ. E -hydroxy-l-tryptophan. -dihydroxy- -hexadien IBS IBS IBS IBS.

Factors Influencing Satisfaction with Life in Female Nursing College Students with Irritable Bowel Syndrome

THREE BASIC APPROACHES TO MEASURING THE HRQOL IMPACT OF MEDICAL CONDITIONS

Functional Disorders of the Lower GI tract: A Forty Year Clinical Perspective

Impact of gastroesophageal reflux symptoms on health resource usage and work absenteeism in Spain

... SELECTED ABSTRACTS...

Irritable Bowel Syndrome: Toward an Understanding of Severity

MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES

Irritable bowel syndrome (IBS) is a classic functional gastrointestinal

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (4), Page

Irritable bowel syndrome (IBS) is the most commonly diagnosed

Current and Emerging Pharmacological Treatments in Irritable Bowel Syndrome

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

Post-Infectious Irritable Bowel Syndrome. John K. Marshall MD Division of Gastroenterology McMaster University

Primary Management of Irritable Bowel Syndrome

FUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta

EPIDEMIOLOGY OF IRRITABLE BOWEL SYNDROME IN THE FORMER COMMUNIST COUNTRIES FROM EASTERN EUROPE: A SYSTEMATIC REVIEW

Studies have shown that familial aggregation is of

Health-related quality of life in adults with irritable bowel syndrome in a Mexican specialist hospital. A cross-sectional study

Diagnosing and Managing IBS in IBD Patients. September 2012

Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties

Accepted Article. Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful? Constanza Ciriza de los Ríos

Adaptation and validation of the Bristol scale stool form translated into the Spanish language among health professionals and patients

Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros

Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation

Comparing the efficacy of polyethylene glycol. glycol (PEG), magnesium hydroxide, lactulose. treatment of functional constipation in children

Post-infectious gastrointestinal symptoms after acute Giardiasis. A 1-year follow-up in general practice

Masanori Kosako 1*, Hiraku Akiho 2, Hiroto Miwa 3, Motoyori Kanazawa 4 and Shin Fukudo 4

JNM Journal of Neurogastroenterology and Motility

Journal of American Science 2017;13(6) Celiac Disease in Patients with Irritable Bowel Syndrome

UNDERSTANDING IBS AND CC Implications for diagnosis and management

The presence of gastrointestinal (GI) symptoms suggestive

A Meta-analysis of the Therapeutic Effects of Amitriptyline for Treating Irritable Bowel Syndrome

Transcription:

1130-0108/2011/103/11/570-575 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2011 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 103. N. 11, pp. 570-575, 2011 ORIGINAL PAPERS The burden and management of patients with IBS: results from a survey in Spanish gastroenterologists Cristina Almansa 1, Manuel Díaz-Rubio 2 and Enrique Rey 2 1 Division of Gastroenterology. Mayo Clinic Jacksonville, Florida, USA. 2 Department of Gastroenterology. Hospital Clínico San Carlos. Madrid. Spain ABSTRACT Background: irritable bowel syndrome (IBS) is a common and complex disorder. Though it is estimated that IBS constitutes an important part of the gastroenterology (GI) practice, the burden of this problem in the GI outpatients clinics in Spain is unclear. Aim: the aim of this study is to obtain a shot of the burden and management of this syndrome in the daily GI practice. Methods: 508 general gastroenterologists from all over the country were approached and asked to complete a survey that included questions about their daily practice and the definition, diagnosis and treatment of IBS. Results: 55% of the surveyed physicians estimate that IBS constitute between a quarter and a half of all their consultations; and pointed out that most of these patients were referred from primary care. Overall, the Spanish gastroenterologists show an adequate knowledge of the different diagnostic criteria, though they do not always follow the current guidelines. Up to 55% of the physicians always perform a complementary test to support their diagnosis and 40% order a diagnostic test only in older patients (> 50 years) or in presence of alarm symptoms. Interestingly, 80% of the gastroenterologists start empirical treatment based on the patients symptoms. Conclusions: though Spanish gastroenterologists seem to have an adequate theoretical knowledge of the disease, they do not systematically follow current guidelines and tend to manage IBS symptoms based on their own criteria. Key words: Irritable bowel syndrome. IBS guidelines. Diagnostic criteria. Clinical management. Almansa C, Díaz-Rubio M, Rey E. The Burden and Management of Patients with IBS: Results from a Survey in Spanish Gastroenterologists. Rev Esp Enferm Dig 2011; 103: 570-575. Acknowledgement: This study has been supported by an unrestricted grant from Menarini España. Received: 26-04-11. Accepted: 05-05-11. Correspondence: Enrique Rey. Department of Gastroenterology. Hospital Clínico Universitario San Carlos. c/ Profesor Martin Lagos s/n. 28040 Madrid, Spain. e-mail: Rey.enrique@med.ucm.es INTRODUCTION Irritable bowel syndrome (IBS) is a common disorder (1). In Spain, it affects up to 10% of the population (2), and 40% of them ask for medical attention (3). Though it is estimated that IBS constitutes an important part of the gastroenterology (GI) practice, the burden of this problem in the GI outpatients clinics in Spain is unclear (4,5). IBS can be difficult to manage; such complexity is mostly due to the lack of a specific diagnostic marker but also due to the lack of a specific treatment. International (6-9) and national (10) clinical guidelines have been implemented with the aim of helping the clinician in the management of IBS. These guidelines have been developed by consensus of experts based on the current symptom-based diagnostic criteria and the review of the literature. The first symptombased criteria were elaborated by Manning in 1978 (11), and these were later substituted by the Rome symptombased criteria: Rome I in 1994 (12), Rome II in 1999 (13) and most recently Rome III in 2006 (14). The use of symptom-based diagnostic criteria allows us to perform a positive diagnosis of IBS instead of an exclusion one. However, it has been reported that up to 72% of physicians from different specialties in the USA (GI, internal medicine and primary care) still consider IBS as a diagnostic of exclusion, which lead to over prescription of diagnostic tests and increases unnecessarily the costs (15). Whether this approach is also followed in Spain, which has a completely different healthcare system than the USA, remains uncertain though a priori seem to be unlikely. The results of a Delphi survey performed in 2003 among GIs and primary care physicians in Spain showed that Spanish physicians do not agree to identify only one as the best diagnostic strategy in patients with suspected IBS, while they agree to treat IBS patients according to their leading symptoms (16). This survey, though limited by its small sample size, suggests that the practical management of IBS is different in our country than in the USA.

Vol. 103. N. 11, 2011 THE BURDEN AND MANAGEMENT OF PATIENTS WITH IBS: RESULTS FROM A SURVEY 571 IN SPANISH GASTROENTEROLOGISTS Fig. 2. Proportion of gastroenterologists that know and use the different symptom based diagnostic criteria. Fig. 1. Rate of patients diagnosed with IBS from the total of patients seen in the GI outpatient s clinics. The aim of our study is to obtain a snapshot of the burden and daily management of IBS in the GI daily practice in Spain. METHODS Design Cross-sectional survey addressed to GI specialists from all over Spain. Sample It is estimated that there are about 2,500 to 3,000 GI specialists working in Spain, though unfortunately it does not exist any formal registry of the specialty that can be easily accessed to confirm this information. Therefore we decided to approach the gastroenterologists in their work place (public and private hospitals and outpatients clinics from all over the country) and asked them to fill our survey, until we reached a size sample of 500. GI fellows and gastroenterologists that spend more than 75% of their time focused in a specific GI area were excluded. Questionnaire We used a modified version of the 26 item questionnaire that we previously designed for the 2003 Delphi survey (16). In this new version we asked the physicians how often do they perform a specific task (responses ranging from always to never) instead of asking them which was their level of agreement with the performance of such task (responses ranged from totally agree to totally disagree). In addition, we transformed the Delphi s open responses into affirmative or negative statements. Analysis We performed a descriptive analysis of the subjects responses. RESULTS Participants 508 GI specialists from all over Spain completed the survey (142 from Andalucía, 71 from the Madrid area, 69 from Cataluña, 58 from the Valencian region, 32 from Galicia, 25 from Castilla-La Mancha, 23 from Castilla León, 23 from the Canary Islands and 21 from the Balearic Islands). Up to 60% of the specialists referred to attend more than 50 patients per week while only 9% of them referred to attend less than 30. When they were specifically asked about which proportion presented with IBS, 55% pointed that this rate was between 25-50%; 29% of them estimated that IBS represented around 50-75% of their consults, 13% of them estimated than less than 25% and only 4% referred that IBS constituted more than 75% of their patients volume (Fig. 1). Patients referral source and reasons According to 66% of the physicians surveyed, 70% or more of the IBS patients were referred from primary care; while only 6% estimated that less than 25% of their IBS patients were referred from primary care. When asked about the reasons for referral, the doctors surveyed considered that 50% were referred for diagnosis, 6% for treatment prescription and 44% for both diagnosis and treatment. IBS clinical classification Pain was the predominant symptom in most patients with IBS according to 52% of the physicians; while 4% of the gastroenterologist referred that they never attend any patient with abdominal pain. 29% of the gastroenterologists pointed the alternating or mixed bowel habit as the most frequent,

572 C. ALMANSA ET AL. REV ESP ENFERM DIG (Madrid) Table I. Physicians evaluation of the different diagnostic tests, classified according the patients predominant symptoms Diagnostic test Diarrhea Constipation Pain Mixed CBC and basic serum chemistry 89% 84% 86% 87% TSH 85% 68% 37% 68% Stool culture 75% 11% 15% 42% Anti-gliadine and antitransglutaminase antibodies 81% 18% 34% 53% Colonoscopy 66% 63% 59% 70% Barium enema 19% 38% 27% 24% Small bowel radiology 25% 4% 17% 16% Abdominal ultrasound 19% 17% 60% 23% Upper endoscopy 6% 3% 12% 4% Anorectal manometry 1% 7% 2% 1% Do not respond 1% 1% 1% 0 while 23% considered the diarrhea and 7% the constipation. 84% of all the physicians surveyed agreed that only a minority (< 25%) of the IBS patients could not be classified according their predominant symptoms. Diagnosis When asked about the overall diagnosis approach, 5% of the responders referred that they followed a symptombased strategy, 55% always prescribed a diagnostic test in order to rule out structural diseases and finally 40% prescribed a diagnostic test only in the presence of alarm symptoms or in subjects older than 50 years. Table I shows the physicians evaluation of the different diagnostic tests according the patients predominant symptoms. Treatment 80% of the physicians initiate empirical treatment, while 18% always wait until they receive the result of the diagnostic tests; 2% do not follow any particular rule. Table II summarizes the response of the gastroenterologists with respect to the different therapeutic options by symptoms groups. Follow up 88% of the gastroenterologists consider that primary care should be responsible for most patients follow up, while 11% considered that this should be responsibility of GI. Interestingly 30% of the respondents chose not to respond this question. DISCUSSION This study shows the opinion of Spanish gastroenterologists regarding the daily management of patients with IBS. IBS is one of the most prevalent conditions in the GI practice. Indeed, 55% of the physicians surveyed estimated that IBS constitutes up to 25-50% of their consultations and an additional one third of physicians estimate this rate as higher than 50%; which is in agreement with data from other Euro- Table II. Treatment of choice (1 st ) and best alternative (2 nd ) according the patients predominant symptom Treatment Diarrhea Constipation Pain Mixed Choice 1 st 2 nd 1 st 2 nd 1 st 2 nd 1 st 2 nd Diet 18% 1% 16% 6% 4% 4% 12% 5% Antidiarrheal 22% 36% 1% 1% 1% 1% 1% 3% Antispasmodics 48% 36% 14% 25% 90% 19% 40% 44% Dietary Fiber 33% 18% 73% 22% 10% 19% 53% 26% Laxatives 1% 1% 10% 56% 1% 3% 1% 2% Anxiolytics 5% 23% 1% 10% 4% 46% 4% 31% Antidepressants 1% 9% 1% 5% 1% 27% 1% 12% Do not respond 1% 1% 1% 1% 1% 1% 1% 2%

Vol. 103. N. 11, 2011 THE BURDEN AND MANAGEMENT OF PATIENTS WITH IBS: RESULTS FROM A SURVEY 573 IN SPANISH GASTROENTEROLOGISTS pean countries (4,5). Quantitatively, this rate means an important number of patients to be seen by the gastroenterologist; mainly if we consider that the GI average patient volume was ranged between 50-100 patients per week. More than half of the physicians confirmed abdominal pain as the cardinal symptom in IBS. In addition, most gastroenterologists agree that is rare that a patient with IBS cannot be classified according the predominant symptoms. In general, our physicians consider the symptom-based diagnostic criteria as a simple and useful diagnostic tool, mostly in young patients. Most Spanish GI physicians know and use the Rome II and III criteria, while only a minority know and use the Manning criteria. Therefore, it seems as the Spanish gastroenterologist accept the current diagnostic criteria (7,10,14), and tend to apply them in their daily practice; which contrast with what has been reported in other countries (17,18). A significant proportion of the doctors surveyed applied a diagnostic approach in agreement with the published guidelines; in general they do not over prescribe diagnostic test, but order a complete blood count, basic serum chemistry and, except when the abdominal pain is the main symptom, a TSH determination. In addition, in patients with diarrhea, our physicians order stool cultures, ova and parasites exam. Though currently there is not enough scientific evidence that support this approach, the truth is that clinically is not an unreasonable strategy and previous diagnostic criteria, such as those of Kruis (19,20) used to include some lab parameters for the diagnosis of IBS. Most gastroenterologists agree to screen for celiac disease (CD) in patients with diarrhea and occasionally in other IBS subtypes. This strategy is in agreement with previous studies that report a higher prevalence of CD in patients with IBS like symptoms, mainly in those presenting with abdominal pain and diarrhea. The risk of CD in IBS seems to be up to 3-4 folds higher than in the normal population (21). In fact the American College of Gastroenterology recommends routine serological screening for CD in patients with diarrhea or mixed symptoms (19); being preferable the use of tissue-transglutaminase antibodies that are the most sensitive and specific (22). More than a half of the gastroenterologists recommend the performance of colonoscopy in patients with IBS, mainly in patients with mixed symptoms where the proportion reach the 70%. Despite that there is lack of evidence to support the routine performance of colonoscopy in patients younger than 50 years old, except when red flags or alarm symptoms are present (23); this same approach is also common in other countries, like USA (15). The therapeutic management of this disorder is also complex, given that to date; there is not any drug available that can successfully control all symptoms of IBS. Current guidelines recommend a symptom based therapeutic approach, which seems to agree with the opinion of the Spanish gastroenterologists. Our physicians recommend the use of antispasmodic and anti-diarrheal drugs in case of diarrhea, dietary fiber and laxatives in case of constipation, antispasmodics when pain is the main symptom and antispasmodics and dietary fiber for those with mixed symptoms. Interestingly, when asked about the use of psychotropic drugs, our physicians rather prescribe benzodiazepines than antidepressants, even when the scientific evidence supports the opposite (24,25). We do not find important differences between the results of this study and the data obtained in our prior survey addressed to primary care doctors and GI. Our prior study was designed using the Delphi methodology which at the end of the day implied the lost of a number of participants. In this study, we used a cross-sectional design which allowed us to get a larger sample size. In our opinion, the similitude found in the outcomes of both studies reinforces the validity of our results (16). Our study has an obvious limitation which is that these data represent only the view of the respondents and therefore should be interpreted cautiously. However, this survey is also the best source of information on this topic that is currently available in Spain, representing the opinion of up to 20% of all Spanish gastroenterologists. In summary, despite their limitations this study shows the high prevalence of IBS in the GI clinics and suggests that the Spanish gastroenterologist have an adequate theoretical knowledge of IBS but experience certain difficulties in the daily management of this disease. The main pitfalls found in the practice of Spanish gastroenterologists are the prescription of unnecessary diagnostic test and treatments not always evidence-based; but otherwise their approach is in consonance with the strategy used by other gastroenterologists in the international community. REFERENCES 1. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-80. 2. Mearin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001;36:55-1161. 3. Badia X, Mearin F, Balboa A, Baro E, Caldwell E, Cucala M, et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics 2002;20:749-58. 4. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983;1:632-4. 5. Dapoigny M, Dyard F, Grimaud JC, Guyot P, van GE. Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology. Gastroenterol Clin Biol 2003;27:265-71. 6. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31. 7. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. 8. Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-05. 9. Fass R, Longstreth GF, Pimentel M, Fullerton S, Russak SM, Chiou CF, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001;161:2081-8. 10. Grupo de trabajo de la guía de práctica clínica sobre el síndrome del intestino irritable. Manejo del paciente con síndrome del intestino irritable. Barcelona; 2005.

574 C. ALMANSA ET AL. REV ESP ENFERM DIG (Madrid) 11. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4. 12. Drossman DA, Richter JE, Talley NJ, Corizziari E, Thompson WG, Whitehead WE. Functional gastrointestinal disorders. Boston: Little; Brown; 1994. 13. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45 Suppl 2:II43-II47. 14. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130:1480-91. 15. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105:848-58. 16. Almansa C, Rey E, Bolanos E, Palma M, Alvarez SA, Diaz-Rubio M. Spanish physicians point of view on irritable bowel syndrome (IBS). Results of a Delphi survey. Rev Esp Enferm Dig 2007;99:210-7. 17. Vandvik PO, Aabakken L, Farup PG. Diagnosing irritable bowel syndrome: poor agreement between general practitioners and the Rome II criteria. Scand J Gastroenterol 2004;39:448-53. 18. Charapata C, Mertz H. Physician knowledge of Rome symptom criteria for irritable bowel syndrome is poor among non-gastroenterologists. Neurogastroenterol Motil 2006;18:211-6. 19. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 (Supl. 1) 1:S1-35. 20. Kruis W, Thieme C, Weinzierl M, Schussler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7. 21. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009;169:651-8. 22. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981-2002. 23. Chey WD, Nojkov B, Rubenstein JH, Dobhan RR, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010;105:859-65. 24. Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G. Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther 2006;24:207-36. 25. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-78.